Aadi Bioscience shareholders approve director elections, say-on-pay, and auditor ratification at 2024 annual meeting

Whitehawk Therapeutics, Inc.

Elected Caley Castelein (9.95M for, 1.91M withheld) and Neil Desai (8.17M for, 3.68M withheld) as Class I directors.
Advisory vote on executive compensation passed with 8.97M for, 2.60M against, 282K abstentions.
Ratified BDO USA as independent auditor for FY 2024: 13.46M for, 635K against, 1.00M abstentions.
Total shares represented 15.1M, ~62% of voting power, establishing a quorum.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.